NEW YORK (TheStreet) -- Tekmira Pharmaceuticals (TKMR) shares are up 12.8% to $22.74 after the company announced that U.S. and Canadian regulators have green lighted the use of its treatment, TKM-Ebola, for patients with confirmed or suspected cases of Ebola.
The company said that its treatment has already been used in emergency cases and has been generally been well tolerated by patients.
The company is developing TKM-Ebola in conjunction with the U.S. Defense Department.STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
"Tekmira is reporting that an appropriate regulatory and clinical framework is now in place to allow the use of TKM-Ebola in patients. We have worked with the FDA and Health Canada to establish this framework and a treatment protocol allowing us to do what we can to help these patients," said Tekmira's President and CEO Dr. Mark J. Murray.
TheStreet Ratings team rates TEKMIRA PHARMACEUTICALS CORP as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:
"We rate TEKMIRA PHARMACEUTICALS CORP (TKMR) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow."